Please login to the form below
Yescarta
This page shows the latest Yescarta news and features for those working in and with pharma, biotech and healthcare.
BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
Kite has already seen success with its own CAR T treatments, which includes Tecartus (brexucabtagene autoleucel) and Yescarta (axicabtagene ciloleucel). ... Meanwhile, Yescarta is used to treat follicular lymphoma and is also approved in the US for the
Latest news
-
Kite’s CAR-T therapy Yescarta shows positive results in second-line lymphoma study
After a median follow-up of two years, Yescarta showed a 60.2% improvement in event-free survival (EFS) compared to SOC. ... Yescarta has been instrumental in transforming outcomes for patients with third-line LBCL.
-
Gilead’s Q1 revenues lifted by COVID-19 med Veklury as HIV drugs take a hit
Gilead was also bolstered by sales of its cell therapy products, which jumped by 36% to $191m in the first quarter, with Yescarta bringing in $160m and Tecartus bringing in $31m.
-
Yescarta gains first FDA approval for indolent follicular lymphoma
marginal zone lymphoma patients were enrolled and treated with Yescarta following two or more prior lines of therapy. ... Kite also recently revealed some positive data for Yescarta in the first-line setting for patients with high-risk large B-cell
-
FDA approves BMS’ blood cancer CAR T therapy after delay
Gilead/Kite’s Yescarta (axicabtagene ciloleucel) was the first FDA-approved CAR T therapy for the treatment of adult patients with relapsed or refractory LBCL, including DLBCL.
-
Gilead’s COVID-19 drug Veklury brought in almost $2bn in Q4
This includes Yescarta (axicabtagene ciloleucel) and Tecartus M (brexucabtagene autoleucel), which helped to grow sales by 34% to $163m in Q4 and 33% to $607m for the entire year. ... Gilead said growth in this area was caused primarily by continued
More from news
Approximately 14 fully matching, plus 57 partially matching documents found.
Latest Intelligence
-
Keeping up with the developing regulatory requirements for gene and cell therapies
By Clive Glover. Since the approval of the first five gene or gene-modified cell therapies in the US – Luxturna, Yescarta, Tecartus, Kymriah and Zolgensma – this new technology has been evolving
-
Cortellis Drugs to Watch in 2020 report
as Kymriah and Yescarta.
-
25 Women Leaders in UK Healthcare (part 2)
It has brought to market not one but two groundbreaking drugs in hepatitis C, Harvoni, and in diffuse large B cell lymphoma, Yescarta, one of the first CAR-T therapies to
-
Bluebird: on a mission to ‘recode’ the DNA of healthcare
years. Kymriah’s US list price is $475, 000 while Gilead’s rival drug, Yescarta, is priced at $373, 000 (with European prices substantially lower than this).
-
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
can make it on to the market early – agreements on the two CAR-T drugs, Novartis’ Kymriah and Gilead’s Yescarta providing an encouraging sign.
More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.
Latest from PMHub
-
Training the next generation of biotech leaders
In August, Novartis’ revolutionary CAR-T therapy, Kymriah, was approved. This was quickly followed by the approval of Kite’s Yescarta in October.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
-
B2B media account director
-
Competitive salary
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- First trial of a vaccine against Alzheimer’s launches
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
- bluebird bio’s beti-cel accepted for priority review by FDA
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- bluebird bio’s beti-cel accepted for priority review by FDA
- Novartis forms coronavirus alliance with life sciences companies
- Pfizer's 2021 revenue predictions soar to $82bn
- US FDA expands COVID-19 booster jabs to all adults
- Six ways to improve diversity in clinical trials
PMHub
Hamell
Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...
Latest intelligence
- Webinar:
- Securing a future for telehealth with immersive market research insights...
- Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
- How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
- Six ways to improve diversity in clinical trials
- Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...
